玻尿酸巨头再陷裁员风波，山东女首富铁腕反腐

Core Viewpoint - The return of Zhao Yancai, the founder and chairperson of Huaxi Biological, has initiated a significant internal restructuring and reform within the company, amidst declining financial performance and organizational turmoil [1][3][20]. Group 1: Organizational Changes - Huaxi Biological has seen over 10 executives leave or change positions since the beginning of the year, indicating a major organizational overhaul [3]. - Employees have reported a shift from direct employment to outsourcing, with inconsistent severance packages being offered, leading to uncertainty and dissatisfaction among staff [2][3]. - The company is reportedly relocating a significant portion of its operations from Beijing to Hangzhou, retaining only a small part of its business in Beijing [2][3]. Group 2: Financial Performance - The company's half-year report revealed a revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%, and a net profit of 221 million yuan, down 35.38% [3][22]. - The functional skincare segment, which accounted for 72.45% of the company's main business revenue, saw a significant decline in growth, with a projected revenue of 2.569 billion yuan in 2024, down 31.62% year-on-year [9][22]. - Marketing expenses have surged, with sales costs rising from 5.21 billion yuan in 2019 to 30.49 billion yuan in 2022, constituting nearly 48% of revenue [9]. Group 3: Market Position and Strategy - Huaxi Biological, once a leader in the hyaluronic acid market with a 44% global share, is facing intensified competition and a shift in consumer preferences, leading to a decline in brand loyalty [5][21]. - The company has decided to phase out underperforming brands like Runxiquan, focusing instead on its core brands, Runbaiyan and Kuaidi, in response to market pressures [8][18]. - Zhao Yancai's return is seen as a potential turning point, with efforts to restore governance and strategic direction, although the effectiveness of these measures remains to be seen in upcoming quarters [20][22].